trastuzumab-dkst Ogivri
Selected indexed studies
- Trastuzumab. (, 2006) [PMID:29999639]
- Physicochemical and functional characterization of trastuzumab-dkst, a trastuzumab biosimilar. (Future Med Chem, 2021) [PMID:34289749]
- Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. (Breast, 2021) [PMID:33892316]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- The Era of Therapeutic Biosimilars Has Arrived: What You Need to Know. (2019) pubmed
- Trastuzumab. (2006) pubmed
- Physicochemical and functional characterization of trastuzumab-dkst, a trastuzumab biosimilar. (2021) pubmed
- Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. (2021) pubmed
- Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population. (2024) pubmed
- Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer. (2021) pubmed
- FDA Approves Trastuzumab Biosimilar. (2018) pubmed
- Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer. (2021) pubmed
- The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab. (2018) pubmed
- Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion. (2021) pubmed